{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:52:24Z","timestamp":1787691144539,"version":"build-2784847793"},"reference-count":15,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Venetoclax is used to treat relapsed\/refractory chronic lymphocytic leukemia (r\/r CLL). Tumour lysis syndrome (TLS) is a serious toxicity associated with venetoclax, and real-world studies suggest that the incidence may be higher than in clinical trials. The purpose of this study is to describe the incidence of venetoclax toxicities in British Columbia (BC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective review of electronic medical charts for patient characteristics and clinical outcomes of patients treated with venetoclax for r\/r CLL in BC. Patients were classified according to their risk for developing TLS. The incidence of TLS was categorized based on laboratory metrics or clinical diagnosis. Other non-TLS toxicities were also collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 33 patients identified, 40%, 33%, and 27% were at low, intermediate, and high risk for TLS, respectively. Laboratory TLS occurred in 1\/33 patients (3%), and no clinical TLS was reported. Grade 3 or 4 toxicities occurred in 19\/33 patients (58%). Of these, neutropenia was the most common, occurring in 16 patients (84%) followed by thrombocytopenia, which occurred in 8 patients (42%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The incidence of TLS in patients treated with venetoclax for r\/r CLL in BC was lower than in other real-world studies. Findings may warrant further investigation to determine if the higher incidence of TLS in real-world reports may be mitigated through modifying TLS risk categorization and associated prophylactic measures. Neutropenia was the most common grade 3 or 4 venetoclax toxicity reported, and the incidence in BC is comparable to other centres.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552221084616","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T06:57:46Z","timestamp":1646636266000},"page":"1163-1169","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world incidence of venetoclax toxicities in British Columbia"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0281-1099","authenticated-orcid":false,"given":"Cassandra","family":"Lee","sequence":"first","affiliation":[{"name":"BC Cancer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Markarian","sequence":"additional","affiliation":[{"name":"BC Cancer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Ladha","sequence":"additional","affiliation":[{"name":"BC Cancer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0712-7958","authenticated-orcid":false,"given":"Lynne","family":"Nakashima","sequence":"additional","affiliation":[{"name":"BC Cancer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8284-4893","authenticated-orcid":false,"given":"Mario","family":"de Lemos","sequence":"additional","affiliation":[{"name":"BC Cancer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Schaff","sequence":"additional","affiliation":[{"name":"BC Cancer, Victoria BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Woo","sequence":"additional","affiliation":[{"name":"BC Cancer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Gerrie","sequence":"additional","affiliation":[{"name":"BC Cancer"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,3,7]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.3747\/co.25.4092"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16345"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30909-9"},{"key":"e_1_3_2_5_2","unstructured":"Venclexta product monograph. Saint-Laurent (QC): AbbVie Corporation; 2016 Sep 27."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0904569"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1768384"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513257"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30019-5"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15802"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3761"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.193615"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0361"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16271"},{"key":"e_1_3_2_15_2","volume-title":"BC Cancer protocol summary for treatment of relapsed\/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma using venetoclax [internet]","unstructured":"BC Cancer (Provincial Health Services Authority). BC Cancer protocol summary for treatment of relapsed\/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma using venetoclax [internet]. British Columbia: BC Cancer (Provincial Health Services Authority); Available from: http:\/\/www.bccancer.bc.ca\/chemotherapy-protocols-site\/Documents\/Lymphoma-Myeloma\/ULYVENETO_Protocol.pdf (2019, accessed 8 April 2021)."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221084616","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552221084616","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221084616","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:37:26Z","timestamp":1779194246000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552221084616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,7]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1177\/10781552221084616"],"URL":"https:\/\/doi.org\/10.1177\/10781552221084616","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,7]]}}}